These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34028105)

  • 21. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Ito K; Kita Y; Kobayashi T
    Int J Urol; 2023 Sep; 30(9):696-703. PubMed ID: 36482843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
    Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
    Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
    Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
    Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
    N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Goto Y
    Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
    [No Abstract]   [Full Text] [Related]  

  • 29. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
    Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
    Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
    J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
    Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
    Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Tomisaki I; Harada M; Sakano S; Terado M; Hamasuna R; Harada S; Matsumoto H; Akasaka S; Nagata Y; Minato A; Harada KI; Fujimoto N
    Int J Urol; 2023 Sep; 30(9):738-745. PubMed ID: 36693764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Taguchi S; Kawai T; Ambe Y; Kishitani K; Sugimoto K; Miyakawa J; Nakamura Y; Noda M; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Furuya Y; Sato Y; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
    Int J Urol; 2023 Dec; 30(12):1180-1186. PubMed ID: 37740409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Furubayashi N; Negishi T; Sakamoto N; Tamura S; Morokuma F; Song Y; Hori Y; Tomoda T; Seki N; Kuroiwa K; Nakamura M
    In Vivo; 2021; 35(5):2869-2874. PubMed ID: 34410980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
    Vaughn DJ; Bellmunt J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Li H; Perini RF; Bajorin DF; de Wit R
    J Clin Oncol; 2018 Jun; 36(16):1579-1587. PubMed ID: 29590008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
    Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
    Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.